The Effect of Liver and Kidney Disease on the Pharmacokinetics of Clozapine and Sildenafil: A Physiologically Based Pharmacokinetic Modeling

References

• RowlandM, PeckC, TuckerG. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011;51(1):45–73. doi:10.1146/annurevpharmtox-010510-10054020854171
   PubMed Web of Science ®Google Scholar
• JonesHM, ChenY, GibsonC, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97(3):247–262. doi:10.1002/cpt25670209
   PubMed Web of Science ®Google Scholar
• McilwainME, HarrisonJ, WheelerAJ, RussellBR. Pharmacotherapy for treatment-resistant. Neuropsychiatr Dis Treat. 2011;7(1):139–149. doi:10.2147/NDT.S12769
   Web of Science ®Google Scholar
• UrichukL, PriorT, DursunS, BakerG. Metabolism of atypical antipsychotics: involvement of cytochrome P450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008;9(5):410–418. doi:10.2174/13892000878474637318537577
   PubMed Web of Science ®Google Scholar
• WagmannL, MeyerMR, MaurerHH. What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse? Toxicol Lett. 2016;258:55–70. doi:10.1016/j.toxlet.2016.06.01327320963
   PubMed Web of Science ®Google Scholar
• PirmohamedM, WilliamsD, MaddenS, TempletonE, ParkBK. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther. 1995;272(3):984–990.7891353
   PubMed Web of Science ®Google Scholar
• ZhangWV, D’EspositoF, EdwardsRJ, RamzanI, MurrayM. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes. Drug Metab Dispos. 2008;36(12):2547–2555. doi:10.1124/dmd.108.02367118809730
   PubMed Web of Science ®Google Scholar
• AkamineY, Sugawara-KikuchiY, UnoT, ShimizuT, MiuraM. Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms. Ann Clin Biochem. 2017;54(6):677–685. doi:10.1177/000456321668637727932669
   PubMed Web of Science ®Google Scholar
• SchaberG, StevensI, GaertnerHJ, DietzK, Breyer-PfaffU. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol. 1998;46(5):453–459. doi:10.1046/j.1365-2125.1998.00822.x9833598
   PubMed Web of Science ®Google Scholar
• ZaiCC, ZaiGC, TiwariAK, et al. Association study of GABRG2 polymorphisms with suicidal behavior in schizophrenia patients with alcohol use disorder second-Generation Antipsychotics and Extrapyramidal Adverse Effects. Neuropsychobiology. 2014;69(3):154–158. doi:10.1159/00035883924776921
   PubMed Web of Science ®Google Scholar
• De BerardisD, RapiniG, OlivieriL, et al. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther Adv Drug Saf. 2018;9(5):237–256. doi:10.1177/204209861875626129796248
   PubMed Web of Science ®Google Scholar
• SultanRS, OlfsonM, CorrellCU, DuncanEJ. Evaluating the effect of the changes in FDA guidelines for clozapine monitoring. J Clin Psychiatry. 2017;78(8):e933–e939. doi:10.4088/JCP.16m1115228742291
   PubMed Web of Science ®Google Scholar
• SmithSM, O’KeaneV, MurrayR. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry. 2002;181(1):49–55. doi:10.1192/bjp.181.1.4912091263
   PubMed Web of Science ®Google Scholar
• ParkYW, KimY, LeeJH. Antipsychotic-induced sexual dysfunction and its management. World J Men’s Health. 2013;30(3):153–159. doi:10.5534/wjmh.2012.30.3.153
   Google Scholar
• KellyDL, ConleyRR. Sexuality and schizophrenia: a review. Schizophr Bull. 2004;30(4):767–779. doi:10.1093/oxfordjournals.schbul.a00713015954189
   PubMed Web of Science ®Google Scholar
• MuirheadGJ, RanceDJ, WalkerDK, WastallP. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil citrate. Br J Clin Pharmacol. 2002;53(Suppl 1):13S–20S. doi:10.1046/j.06-5251.2001.00028.x11879255
   PubMed Web of Science ®Google Scholar
• CheitlinMD, HutterAM, BrindisRG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation. 1999;99(1):168–177. doi:10.1161/01.CIR.99.1.1689884398
   PubMed Web of Science ®Google Scholar
• Le CouteurDG, McLeanAJ. The aging liver: drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet. 1998;34(5):359–373. doi:10.2165/00003088-199834050-000039592620
   PubMed Web of Science ®Google Scholar
• YuanR, VenitzJ. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs. Int J Clin Pharmacol Ther. 2000;38(5):245–253. doi:10.5414/cpp3824510839468
   PubMed Web of Science ®Google Scholar
• MontamatSC, CusackBJ, YestalRE. Management of drug therapy in the elderly. N Engl J Med. 1989;321:303–309. doi:10.1056/NEJM1989080332105072664519
   PubMed Web of Science ®Google Scholar
• DarwichAS, NeuhoffS, JameiM, Rostami-HodjeganA. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the Advanced Dissolution, Absorption, Metabolism (ADAM) model. Curr Drug Metab. 2011;11(9):716–729. doi:10.2174/138920010794328913
   Web of Science ®Google Scholar
• ShiZ, TiwariAK, ShuklaS, et al. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res. 2011;71(8):3029–3041. doi:10.1158/0008-5472.CAN-10-382021402712
   PubMed Web of Science ®Google Scholar
• ShebleyM, FuW, BadriP, BowDAJ, FischerV. Physiologically based pharmacokinetic modeling suggests limited drug–drug interaction between clopidogrel and dasabuvir. Clin Pharmacol Ther. 2017;102(4):679–687. doi:10.1002/cpt.68928411400
   PubMed Web of Science ®Google Scholar
• GoldenG, HonigfeldG. Bioequivalence of clozapine orally disintegrating 100-mg tablets compared with clozapine solid oral 100-mg tablets after multiple doses in patients with schizophrenia. Clin Drug Investig. 2008;28(4):231–239. doi:10.2165/00044011-200828040-00004
   PubMed Web of Science ®Google Scholar
• RadicioniM, CastiglioniC, GioriA, CuponeI, FrangioneV, RovatiS. Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional film-coated 100 mg tablet administered to healthy male volunteers. Drug Des Devel Ther. 2017;11:1183–1192. doi:10.2147/DDDT.S124034
   PubMed Web of Science ®Google Scholar
• Rowland YeoK, AarabiM, JameiM, Rostami-HodjeganA. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol. 2011;4(2):261–274. doi:10.1586/ecp.10.14322115405
   PubMedGoogle Scholar
• MuirheadGJ, WilnerK, ColburnW, Haug-PihaleG, RouviexB. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol. 2002;53:21S–30S. doi:10.1046/j.0306-5251.2001.00029.x11879256
   PubMed Web of Science ®Google Scholar
• JohnsonTN, BousseryK, Rowland-YeoK, TuckerGT, Rostami-HodjeganA. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49(3):189–206. doi:10.2165/11318160-000000000-0000020170207
   PubMed Web of Science ®Google Scholar
• JaquenoudSirotE, KnezevicB, MorenaGP, et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psycho pharmacol. 2009;29(4):319–326. doi:10.1097/JCP.0b013e3181acc372
   PubMed Web of Science ®Google Scholar
• PiatkovI, CaetanoD, AssurY, et al. ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine. Pharmgenomics Pers Med. 2017;10:235–242. doi:10.2147/PGPM.S14231428919802
   PubMed Web of Science ®Google Scholar
• MoonsT, De RooM, ClaesS, DomG. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics. 2011;12(8):1193–1211. doi:10.2217/pgs.11.5521843066
   PubMed Web of Science ®Google Scholar
• GopalakrishnanR, JacobKS, KuruvillaA, VasantharajB, JohnJK. Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. Am J Psychiatry. 2006;163(3):494–499. doi:10.1176/appi.ajp.163.3.49416513872
   PubMed Web of Science ®Google Scholar
• RheeSJ, ChungH, YiS, YuKS, ChungJY. Physiologically based pharmacokinetic modelling and prediction of metformin pharmacokinetics in renal/hepatic-impaired young adults and elderly populations. Eur J Drug Metab Pharmacokinet. 2017;42(6):973–980. doi:10.1007/s13318-017-0418-x28536774
   PubMed Web of Science ®Google Scholar
• SinhaaVK, SnoeysbJ, Van OsselaercN, Van PeeraA, MackiedC, HealdeD. From preclinical to human - prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example. Biopharm Drug Dispos. 2012;33(2):111–121. doi:10.1002/bdd.178222383166
   PubMed Web of Science ®Google Scholar
• VanholderR, GlorieuxG. The intestine and the kidneys: a bad marriage can be hazardous. Clin Kidney J. 2015;8(2):168–179. doi:10.1093/ckj/sfv00425815173
   PubMed Web of Science ®Google Scholar
• De PalmaGD, RegaM, MasoneS, et al. Mucosal abnormalities of the small bowel in patients with cirrhosis and portal hypertension: a capsule endoscopy study. Gastrointest Endosc. 2005;62(4):529–534. doi:10.1016/s0016-5107(05)01588-916185966
   PubMed Web of Science ®Google Scholar
• NormanK, PirlichM. Gastrointestinal tract in liver disease: which organ is sick? Curr Opin Clin Nutr Metab Care. 2008;11(5):613–619. doi:10.1097/MCO.0b013e32830a70bc18685458
   PubMed Web of Science ®Google Scholar
• LeysenJE, JanssenPMF, HeylenL, et al. Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects. Int J Psychiatry Clin Pract. 1998;2:S3–S17.
   PubMedGoogle Scholar
• GareriP, FalconiU, De FazioP, De SarroG. Conventional and new antidepressant drugs in the elderly. Prog Neurobiol. 2000;61(4):353–396. doi:10.1016/s0301-0082(99)00050-710727780
   PubMed Web of Science ®Google Scholar
• GareriP, De FazioP, RussoE, MariglianoN, De FazioS, De SarroG. The safety of clozapine in the elderly. Expert Opin Drug Saf. 2008;7(5):525–538. doi:10.1517/14740338.7.5.52518759705
   PubMed Web of Science ®Google Scholar
• ElbekaiR, KorashyH, El-KadiA. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab. 2005;5(2):157–167. doi:10.2174/1389200043489054
   Web of Science ®Google Scholar
• VerbeeckRK, MusuambaFT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65(8):757–773. doi:10.1007/s00228-009-0678-819543887
   PubMed Web of Science ®Google Scholar
• FryeRF, ZgheibNK, MatzkeGR, et al. Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther. 2006;80(3):235–245. doi:10.1016/j.clpt.2006.05.00616952490
   PubMed Web of Science ®Google Scholar
• Le CouteurDG, FraserR, HilmerS, RivoryLP, McLeanAJ. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet. 2005;44(2):187–200. doi:10.2165/00003088-200544020-0000415656697
   PubMed Web of Science ®Google Scholar
• Wu ChouAI, LuML, ShenWW. Hepatotoxicity induced by clozapine: a case report and review of literature. Neuropsychiatr Dis Treat. 2014;10:1585–1587. doi:10.2147/NDT.S6765425210451
   PubMed Web of Science ®Google Scholar
• Telles-CorreiaD, BarbosaA, Cortez-PintoH, CamposC, RochaNBF, MachadoS. Psychotropic drugs and liver disease: a critical review of pharmacokinetics and liver toxicity. World J Gastrointest Pharmacol Ther. 2017;8(1):26–38. doi:10.4292/wjgpt.v8.i1.2628217372
   PubMedGoogle Scholar
• Ortiz-OrendainJ, Castiello-de ObesoS, Colunga-LozanoLE, HuY, MaayanN, AdamsCE. Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev. 2017;6(6):CD009005. doi:10.1002/14651858.CD009005.pub228658515
   PubMed Web of Science ®Google Scholar
• HiemkeC, BaumannP, BergemannN, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmaco Psychiatry. 2011;44(6):195–235. doi:10.1055/s-0031-1286287
   Web of Science ®Google Scholar
• SunH, FrassettoL, BenetLZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006;109(1–2):1–11. doi:10.1016/j.pharmthera.2005.05.01016085315
   PubMed Web of Science ®Google Scholar
• DreisbachAW, LertoraJJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4(8):1065–1074. doi:10.1517/17425255.4.8.106518680441
   PubMed Web of Science ®Google Scholar
• ZhangL, XuN, XiaoS, et al. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease. J Clin Pharmacol. 2012;52(1Suppl):79S–90S. doi:10.1177/009127001141541022232757
   PubMed Web of Science ®Google Scholar
• PrueksaritanontT, ChuX, GibsonC, et al. Drug-drug interaction studies: regulatory guidance and an industry perspective. AAPS J. 2013;15(3):629–645. doi:10.1208/s12248-013-9470-x23543602
   PubMed Web of Science ®Google Scholar